Rx (Prescription Medicine)
USD $ 120.00
Bevetex 300mg 注射液是一种靶向疗法，用于治疗某些类型的癌症。其活性成分为 Bevacizumab，一种重组人源化单克隆抗体。Bevacizumab 通过抑制血管内皮生长因子（VEGF），一种在新血管形成中起关键作用的蛋白质。肿瘤需要血液供应以生长和转移，通过阻断 VEGF，Bevetex 有助于使肿瘤缺乏营养和氧气，从而减缓或停止其生长。它适用于转移性结直肠癌、晚期非鳞状非小细胞肺癌、复发性胶质母细胞瘤、转移性肾细胞癌以及晚期宫颈癌的治疗，通常与化疗联合使用。Bevetex 300mg 注射液的剂量和给药方式应由合格的医疗专业人员根据具体的癌症类型、分期以及患者的整体健康状况来确定。常见的不良反应可能包括高血压、蛋白尿、疲劳和胃肠道问题。严重的不良反应可能发生，因此应与医生讨论潜在风险。Bevetex 300mg 注射液应储存在室温并避光保存，不可冷冻。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 300 mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
未库存此 exact 强度的其他品牌，因此这些是其他强度的 Bevacizumab. 未经开方医生建议，请勿更改剂量。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
